Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Urinary Retention Therapeutics Market

Urinary Retention Therapeutics Market Trends

  • Report ID: GMI5771
  • Published Date: May 2023
  • Report Format: PDF

Urinary Retention Therapeutics Market Trends

The rising incidence of urine retention all over the globe is one of the main factors driving the market size. Increasing research and development in pharmaceutical businesses for improving various types of specific medicines, as well as an raising demand for minimally invasive procedures push the market share. The growth in patient knowledge about the prevention and treatment of urine retention, as well as an upsurge in the incidence of post-operative urinary retention, all have an impact on the market. Furthermore, a rise in healthcare spending, an increase in the number of research projects and an increase in the geriatric population all have a beneficial impact on the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for urinary retention therapeutic will record a 5.8% CAGR between 2023 to 2032.

Stress incontinence segment was 36.4% in 2022 due to high prevalence and negative impact of stress incontinence.

North America urinary retention therapeutic market surpassed of USD 889.2 million in 2022, owing to a high prevalence of urinary retention conditions in the region.

Merck KGaA, Sanofi, Pfizer Inc., GlaxoSmithKline plc., Eli Lilly, Astellas Pharma Inc., Bayer AG, Johnson & Johnson, Novartis AG, and Sun Pharmaceutical Industries Ltd.

Urinary Retention Therapeutics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 213
  • Countries covered: 19
  • Pages: 110
 Download Free Sample